Security Snapshot

Estrella Immunopharma, Inc. - Common Stock, par value $0.0001 per share (ESLA) Institutional Ownership

CUSIP: 297584104

13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

15

Shares (Excl. Options)

4,794,274

Price

$1.04

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-384,550
Value change
-$405,357
Number of holders
15
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
41,110,401
SEC-reported price per share
$0.72
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • ESLA - Estrella Immunopharma, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 297584104.
  • 15 institutions reported positions in Q2 2026.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 16 to 15 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $5,489,554 to $4,986,044.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 15 institutions filings for Q2 2026.

Open SEC evidence

Security key

297584104

Latest holder period

Q2 2026

13F holders

15

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
ESLA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 5% -50% $1,907,810 -$2,072,938 2,051,409 -52% Armistice Capital, LLC 30 Jun 2026

As of 30 Jun 2026, 15 institutional investors reported holding 4,794,274 shares of Estrella Immunopharma, Inc. - Common Stock, par value $0.0001 per share (ESLA). This represents 12% of the company’s total 41,110,401 outstanding shares.

13F concentration

Top 18 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
12%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARMISTICE CAPITAL, LLC 9.7% 3,975,220 -3% 0.11% $4,134,229
VANGUARD CAPITAL MANAGEMENT LLC 1% 416,852 +9% 0% $433,526
GEODE CAPITAL MANAGEMENT, LLC 0.34% 141,321 -10% 0% $146,973
VANGUARD FIDUCIARY TRUST CO 0.16% 64,921 0% 0% $67,518
BlackRock, Inc. 0.13% 52,033 +30% 0% $54,114
STATE STREET CORP 0.11% 43,252 0% 0% $44,982
RENAISSANCE TECHNOLOGIES LLC 0.1% 39,100 -38% 0% $40,664
NORTHERN TRUST CORP 0.08% 34,861 +78% 0% $36,255
US BANCORP \DE\ 0.05% 20,000 +18% 0% $20,800
Tower Research Capital LLC (TRC) 0.01% 3,308 -32% 0% $3,440
UBS Group AG 0% 1,721 -89% 0% $1,790
TORONTO DOMINION BANK 0% 1,089 0% 0% $1,133
WOLVERINE ASSET MANAGEMENT LLC 0% 468 0% 0% $487
BARCLAYS PLC 0% 126 0% $131
Caitong International Asset Management Co., Ltd 0% 2 0% $2
WELLS FARGO & COMPANY/MN 0% 0 -100% $0
ROYAL BANK OF CANADA 0% 0 -100% $0
MORGAN STANLEY 0% 0 -100% $0

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Latest
Q2 2026
Rows shown
1-11 of 11
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 4,794,274 $4,986,044 -$405,357 $1.04 15
2026 Q1 5,178,824 $5,489,554 +$4,327,926 $1.06 16
2025 Q4 999,605 $1,559,085 +$479,373 $1.56 15
2025 Q3 743,186 $878,824 +$136,305 $1.15 13
2025 Q2 634,819 $559,552 +$21,644 $0.96 11
2025 Q1 613,145 $568,449 +$294,571 $0.93 11
2024 Q4 292,276 $341,108 +$108,454 $1.20 11
2024 Q3 200,095 $232,108 +$69,208 $1.16 10
2024 Q2 123,037 $129,188 -$16,862 $1.05 7
2024 Q1 135,217 $165,522 +$8,208 $1.24 6
2023 Q4 128,581 $143,186 +$143,186 $1.11 7
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .